Grifols (NASDAQ:GRFS - Get Free Report) had its price objective upped by JPMorgan Chase & Co. from $7.60 to $10.30 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a "neutral" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 17.45% from the stock's previous close.
Separately, Wall Street Zen upgraded Grifols from a "hold" rating to a "buy" rating in a research note on Friday, May 23rd.
Check Out Our Latest Analysis on GRFS
Grifols Price Performance
GRFS stock traded up $0.07 during midday trading on Tuesday, reaching $8.77. 1,275,233 shares of the company's stock traded hands, compared to its average volume of 1,155,871. The company has a 50-day simple moving average of $7.86 and a two-hundred day simple moving average of $7.59. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13. Grifols has a 1-year low of $5.79 and a 1-year high of $9.96. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 7.50, a PEG ratio of 0.31 and a beta of 0.53.
Institutional Trading of Grifols
Hedge funds have recently modified their holdings of the stock. Blue Trust Inc. raised its position in Grifols by 344.4% in the 4th quarter. Blue Trust Inc. now owns 8,697 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 6,740 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Grifols by 5.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after buying an additional 1,657 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Grifols during the fourth quarter worth $91,000. Highland Peak Capital LLC raised its position in shares of Grifols by 29.5% during the fourth quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company's stock worth $5,849,000 after acquiring an additional 179,114 shares during the last quarter. Finally, HighTower Advisors LLC lifted its stake in shares of Grifols by 28.3% during the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock valued at $133,000 after acquiring an additional 3,936 shares during the period.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Further Reading
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.